

Dear NIPON Corporation,

**Information on Hitachi, Ltd.'s Healthcare Business Restructuring
and the New Company**

We thank you for your continued support.

As announced in the news release dated December 18, 2019, Hitachi, Ltd. ("Hitachi") has agreed to transfer part of its diagnostic imaging business and healthcare IT business to FUJIFILM Corporation ("Fujifilm").

Due to the worldwide spread of COVID-19, the scheduled execution date was tentative; however, at this time, we would like to inform you that the scheduled execution date will be on March 31, 2021, assuming that the acquisition of necessary clearances, permits, etc. based on domestic and overseas competition laws and other laws and regulations will be completed as planned.

With the execution of this transaction, the target business will become a new company, FUJIFILM Healthcare Corporation ("Fujifilm Healthcare"), and will start operations as a member of Fujifilm.

For existing contracts valid as of March 31, 2021 that have been executed with our business partners, the contracts will remain effective. The transaction basically does not require any assignment or transfer of your contracts. However, we may need to consult with you based on the conditions of individual contracts.

Please note, the in-vitro diagnostic systems business and radiotherapy business (particle therapy treatment/X-ray treatment systems) are not covered by this transaction and will remain under Hitachi.

If you have any questions, please do not hesitate to contact us for more information. We are committed to your success and continued partnership and look forward to working together and building upon our relationship.

Best regards,

Koichi Tachihara

Koichi Tachihara
Senior Manager
Global Sales Department
US Global Sales Division
Ultrasound Diagnostic Systems Division
Healthcare Business Unit

